A detailed history of Sumitomo Mitsui Ds Asset Management Company, LTD transactions in Biogen Inc. stock. As of the latest transaction made, Sumitomo Mitsui Ds Asset Management Company, LTD holds 17,761 shares of BIIB stock, worth $2.46 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
17,761
Previous 19,702 9.85%
Holding current value
$2.46 Million
Previous $3.82 Million 28.88%
% of portfolio
0.03%
Previous 0.04%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 28, 2025

SELL
$146.47 - $191.55 $284,298 - $371,798
-1,941 Reduced 9.85%
17,761 $2.72 Million
Q3 2024

Oct 17, 2024

BUY
$189.07 - $236.8 $92,455 - $115,795
489 Added 2.55%
19,702 $3.82 Million
Q2 2024

Jul 30, 2024

BUY
$190.52 - $236.72 $289,971 - $360,287
1,522 Added 8.6%
19,213 $4.45 Million
Q1 2024

May 02, 2024

SELL
$212.02 - $267.71 $13,145 - $16,598
-62 Reduced 0.35%
17,691 $3.81 Million
Q4 2023

Feb 01, 2024

SELL
$222.59 - $267.94 $17,807 - $21,435
-80 Reduced 0.45%
17,753 $4.59 Million
Q3 2023

Oct 30, 2023

BUY
$253.3 - $285.89 $251,020 - $283,316
991 Added 5.88%
17,833 $4.58 Million
Q2 2023

Aug 04, 2023

BUY
$275.25 - $318.06 $1.47 Million - $1.69 Million
5,327 Added 46.26%
16,842 $4.8 Million
Q1 2023

May 02, 2023

BUY
$256.56 - $292.34 $39,253 - $44,728
153 Added 1.35%
11,515 $3.2 Million
Q4 2022

Jan 26, 2023

BUY
$252.44 - $306.72 $233,254 - $283,409
924 Added 8.85%
11,362 $0
Q3 2022

Oct 19, 2022

BUY
$194.69 - $268.46 $33,876 - $46,712
174 Added 1.7%
10,438 $2.79 Million
Q2 2022

Jul 13, 2022

BUY
$187.54 - $223.02 $148,719 - $176,854
793 Added 8.37%
10,264 $2.09 Million
Q1 2022

Apr 19, 2022

SELL
$193.77 - $244.14 $7,750 - $9,765
-40 Reduced 0.42%
9,471 $2 Million
Q4 2021

Jan 20, 2022

SELL
$223.92 - $287.77 $2,910 - $3,741
-13 Reduced 0.14%
9,511 $2.28 Million
Q3 2021

Oct 15, 2021

SELL
$282.99 - $369.05 $26,318 - $34,321
-93 Reduced 0.97%
9,524 $2.7 Million
Q2 2021

Jul 19, 2021

SELL
$259.0 - $414.71 $12,432 - $19,906
-48 Reduced 0.5%
9,617 $3.33 Million
Q1 2021

May 07, 2021

SELL
$242.95 - $284.63 $105,926 - $124,098
-436 Reduced 4.32%
9,665 $2.7 Million
Q4 2020

Feb 02, 2021

SELL
$236.26 - $355.63 $120,020 - $180,660
-508 Reduced 4.79%
10,101 $2.47 Million
Q3 2020

Oct 29, 2020

SELL
$264.77 - $305.71 $19,592 - $22,622
-74 Reduced 0.69%
10,609 $3.01 Million
Q2 2020

Aug 12, 2020

SELL
$258.66 - $342.55 $46,300 - $61,316
-179 Reduced 1.65%
10,683 $2.86 Million
Q1 2020

Apr 21, 2020

SELL
$268.85 - $341.04 $157,277 - $199,508
-585 Reduced 5.11%
10,862 $3.44 Million
Q4 2019

Jan 24, 2020

SELL
$220.06 - $304.07 $110,250 - $152,339
-501 Reduced 4.19%
11,447 $3.4 Million
Q3 2019

Oct 16, 2019

BUY
$217.44 - $243.88 $174,169 - $195,347
801 Added 7.19%
11,948 $2.78 Million
Q2 2019

Aug 13, 2019

SELL
$219.29 - $241.72 $665,983 - $734,103
-3,037 Reduced 21.41%
11,147 $2.61 Million
Q1 2019

May 07, 2019

BUY
$216.71 - $338.96 $153,647 - $240,322
709 Added 5.26%
14,184 $3.35 Million
Q4 2018

Jan 25, 2019

SELL
$278.5 - $352.75 $300,780 - $380,970
-1,080 Reduced 7.42%
13,475 $4.05 Million
Q3 2018

Oct 15, 2018

SELL
$293.51 - $383.83 $34,047 - $44,524
-116 Reduced 0.79%
14,555 $5.14 Million
Q2 2018

Jul 31, 2018

BUY
$257.52 - $306.91 $30,387 - $36,215
118 Added 0.81%
14,671 $4.26 Million
Q1 2018

Apr 25, 2018

SELL
$260.13 - $367.91 $186,253 - $263,423
-716 Reduced 4.69%
14,553 $3.98 Million
Q4 2017

Jan 25, 2018

SELL
$307.64 - $344.58 $392,548 - $439,684
-1,276 Reduced 7.71%
15,269 $4.86 Million
Q3 2017

Oct 27, 2017

BUY
$281.15 - $329.69 $4.65 Million - $5.45 Million
16,545
16,545 $5.18 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $19.9B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Sumitomo Mitsui Ds Asset Management Company, LTD Portfolio

Follow Sumitomo Mitsui Ds Asset Management Company, LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Ds Asset Management Company, LTD, based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Ds Asset Management Company, LTD with notifications on news.